L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

L1 cell adhesion molecule (L1CAM) expression has been implicated as risk factor for disease recurrence in endometrial cancer (EC), most likely due to its role in promoting tumour cell motility. We tested the performance of L1CAM expression in predicting the risk of recurrence in the randomised post operative radiation therapy in endometrial carcinoma (PORTEC)-1 and -2 trials.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): Oct 2014

Volume: 50

Issue: 15

Affiliations

[1 ] Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: T.Bosse@lumc.nl.

[2 ] Department of Medical and Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.

[3 ] Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

[4 ] Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.

[5 ] Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands.

[6 ] Department of Radiotherapy, Medisch Spectrum Twente, Enschede, The Netherlands.

Article

Publisher Item ID: S0959-8049(14)00814-4

DOI: 10.1016/j.ejca.2014.07.014

PubMed ID: 25126672

SO-VID: 7d1fc6c5-7c43-468a-8f2a-a341bca79c54

History

Keywords: Endometrial cancer,L1CAM,PORTEC,Prognostic marker

Data availability:

Keywords: Endometrial cancer, L1CAM, PORTEC, Prognostic marker

Comments

Comment on this article

scite_

Cited by 66

See all cited by

- Version 1